Therefore, therapeutic intervention targeting BAF60a in the liver may be a promising strategy to treat hyperammonemia and HSC activation-induced fibrosis in patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. This evidence concerns the gene SMARCD1 and metabolic dysfunction-associated steatotic liver disease.